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In the face of the current Neonatal Abstinence Syndrome (NAS) epidemic, there is 
considerable variability in the assessment and management of infants with NAS. In 
this manuscript, we particularly focus on NAS assessment, with special attention given 
to the popular Finnegan Neonatal Abstinence Score (FNAS). A major instigator of the 
problem of variable practices is that multiple modified versions of the FNAS exist and 
continue to be proposed, including shortened versions. Furthermore, the validity of 
such assessment tools has been questioned, and as a result, the need for better tools 
has been suggested. The ultimate purpose of this manuscript, therefore, is to increase 
researchers’ and clinicians’ understanding on how to judge the usefulness of NAS 
assessment tools in order to guide future tool development and to reduce variable 
practices. In short, we suggest that judgment of NAS assessment tools should be 
made on a clinimetrics viewpoint as opposed to psychometrically. We provide exam-
ples, address multiple issues that must be considered, and discuss future tool develop-
ment. Furthermore, we urge researchers and clinicians to come together, utilizing their 
knowledge and experience, to assess the utility and practicality of existing assessment 
tools and to determine if one or more new or modified tools are needed with the goal of 
increased agreement on the assessment of NAS in practice.
Keywords: Finnegan Neonatal Abstinence Score, formative model, Neonatal Abstinence Syndrome Score, 
predictive accuracy, reflective model
iNTRODUCTiON
The number of infants developing Neonatal Abstinence Syndrome (NAS) is reaching epidemic 
proportions with increasing number of affected infants receiving pharmacotherapy and increasing 
length of stay in hospital (1–4). Therefore, there has been much research recently addressing the 
assessment and management of infants with NAS. Unfortunately, there is considerable variability 
in practice with respect to both of these aspects (2, 5–8). Inherently, this implies an apparent lack 
of agreement among researchers and clinicians in terms of best methods.
FiGURe 2 | Visual and mathematical representations of a psychometrics-
based reflective model in which crying, general convulsions (GC), mottling, 
etc. are caused by and hence are reflections of neonatal abstinence 
syndrome (NAS). Each symptom has its own equation in which the influence 
of NAS is denoted by λ, and the symptoms may have measurement error, e. 
The symptoms are expected to be strongly correlated due to the influence 
NAS has on each one.
FiGURe 1 | Visual and mathematical representations of a generic 
psychometrics-based reflective model in which items X1, X2, and X3 are 
caused by and hence are reflections of the hypothetical construct θ. Each 
item has its own equation in which the influence of θ is denoted by λ, and the 
items may have measurement error, e. The items are expected to be strongly 
correlated due to the influence θ has on each one. Note that the number of 
items is not restricted, and a scenario with three items was chosen for 
simplicity.
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In this manuscript, we focus on the assessment of infants 
with NAS. Multiple assessment tools have been developed and 
are in use, with the Neonatal Abstinence Syndrome Score, also 
known as the Finnegan Neonatal Abstinence Score (FNAS), being 
the most commonly used (5, 7, 9–12). However, the FNAS has 
been modified multiple times and is not used in exactly the same 
manner at every institution (5, 13). For instance, the MOTHER 
NAS score (MNS) (14, 15) made considerable revisions to the 
FNAS and may be increasing in popularity.
Due to the existence of multiple assessment tools that are 
implemented in practice, it is apparent that researchers and 
clinicians have not come to a common agreement on how to best 
assess NAS. Therefore, we address how to view the theoretical 
modeling framework for NAS from which assessment tools 
arise. Specifically, we contrast viewpoints based on psychometric 
(16–21) and clinimetric (17–19, 22) principles, concluding that 
NAS assessment tools should be viewed clinimetrically. We hope 
that conveying this modeling framework will give researchers 
and clinicians a realistic construct on how to properly judge NAS 
assessment tools, as utilizing a psychometric viewpoint will only 
lead to the conclusion that existing tools are invalid (21, 22). 
Ultimately, we hope that with this increased understanding on 
how to view NAS assessment, future work on creating or modi-
fying assessment tools will lead to improved and standardized 
NAS assessment and thus management.
In the following section, we give relevant details on theo-
retical models corresponding to psychometric and clinimetric 
viewpoints, respectively, with regards to NAS assessment. We 
argue that a clinimetric-based formative model (17–19, 22) 
should be preferred, and then discuss how to judge tools and give 
examples from the literature. Finally, we provide a discussion 
on future tool development, followed by concluding remarks.
PSYCHOMeTRiC- AND CLiNiMeTRiC-
BASeD MODeLS FOR NAS ASSeSSMeNT
Psychometrics—Reflective Model
Psychometric properties are regularly emphasized in practice 
(22), and hence, a reflective model (18, 19) is often used as the 
default to determine the validity of an assessment tool. Figures 1 
and 2 demonstrate a generic reflective model and an assumed 
reflective model for NAS, respectively. Applying this model to 
NAS, it is assumed that NAS causes each item to present, and 
therefore, items should be a reflection of NAS and thus should be 
highly correlated; i.e., items should have good internal consist-
ency or reliability (17–19). As a result, equal weighting of items 
is preferred (18, 23).
Clinimetrics—Formative Model
Generic and NAS-based representations of formative models 
arising from clinimetrics-based reasoning are given in Figures 3 
and 4, respectively. With this model, the items are not required 
to be correlated, and each item contributes, with potentially 
varying magnitudes, toward NAS severity (22). Specifically, the 
weights depicted in Figures 3 and 4 can vary in value according 
to item impact, and the weighted items are summed to form 
a modeled severity of NAS. Figure  4 specifically depicts the 
FNAS, which applies different numerical weighting for cry-
ing, general convulsions, mottling, etc. due to their perceived 
differing influences on NAS severity. In practice, the modeled 
severity may not be the true severity, implying a degree of 
discrepancy, also known as the disturbance, between the model 
and the truth. See, for instance (17–19), for specific details on 
formative models.
which Theoretical Modeling Framework 
works Best for Judging NAS Assessment?
Table 1 provides a concise comparison of reflective and formative 
models. Evidence has shown that NAS assessment tools do not 
TABLe 1 | A comparison of reflective (psychometrics) and formative (clinimetrics) 
models.
Aspect Reflective model Formative model
Item role All items are influenced by 
and, therefore, reflect Neonatal 
Abstinence Syndrome (NAS)
All items build up  
NAS severity
Item correlation All items are highly correlated 
(internal reliability)
Items do not need  
to be correlated
Item weighting Equal weighting Unequal weighting, depending 
on perceived impact the item 
has on NAS severity
FiGURe 4 | Visual and mathematical representations of a clinimetrics-based 
formative model in which crying (EC, excessive crying; CC, continuous 
crying), general convulsions (GC), mottling (M), etc. combine to form 
Neonatal Abstinence Syndrome (NAS) severity. The disturbance term 
represents the influence of all factors not accounted for by the given 
assessment tool. The numerical weights applied to the corresponding items 
in the assessment tool are represented by bEC, bCC, bGC, and bM. In the visual 
representation, bC is equivalent to either bEC or bCC, depending on the severity 
of crying.
FiGURe 3 | Visual and mathematical representations of a generic 
clinimetrics-based formative model in which items X1, X2, and X3 combine to 
form the true hypothetical construct θTrue. The disturbance term represents 
the influence of all other factors besides X1, X2, and X3 on θTrue. The numerical 
weights applied to the items in the assessment tool are represented by b1, 
b2, and b3. Note that the number of items is not restricted, and a scenario 
with three items was chosen for simplicity.
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coincide with a reflective model. Admittedly, NAS can initially 
be thought of in terms of a reflective model, as NAS causes 
symptoms, and thus items in the FNAS, for instance, to present. 
However, the occurrence, severity, and duration of symptoms 
are quite variable across and within infants (13, 14, 21, 24), and 
thus do not reflect NAS to the same degree. As a result, Jones 
et  al. (20) found via low Cronbach’s alphas on the FNAS and 
MOTHER NAS scale that not all items are highly correlated, and 
Bada et al. (25) also found via odds ratios that not all items are 
highly interrelated. We note that Cronbach’s alpha is a measure 
of the degree of correlation among a group of items in order to 
assess internal consistency (26).
The signs of NAS, or symptoms if truly arising from NAS, 
build up NAS severity. Furthermore, clinical reality is that certain 
symptoms are more critical than others when determining the 
severity of NAS, and these symptoms and their severity may not 
highly correlate. Therefore, the formative modeling approach 
should be preferred as it provides a clinically meaningful basis 
on which NAS assessment tools can be judged. This approach 
also provides flexibility in that information other than symptom 
severity can be employed.
JUDGiNG NAS ASSeSSMeNT VIA A 
FORMATive MODeLiNG FRAMewORK
General Approach
An ideal approach to obtaining a NAS assessment tool based 
on a formative approach would be to conduct an empirical 
study utilizing a large amount of clean or robust data from the 
target population, and to use that data to determine which items 
should be incorporated within the resulting tool and how much 
weight to assign each item. The primary interest in using tools 
to assess NAS severity is to determine when pharmacologic 
treatment is needed. Therefore, if we were able to obtain in this 
hypothetical study accurate data on when pharmacologic treat-
ment is needed, logistic regression modeling could be employed 
to obtain estimated weights (see mathematical models presented 
in Figures  3 and 4) which indicate the importance of each 
item. The resulting tool could then be used on a separate large 
dataset of clean or robust data in order to judge and (hopefully) 
validate the predictive accuracy of the tool. An example of such 
an approach is the derivation of the Score for Neonatal Acute 
Physiology—Perinatal Extension (27).
Unfortunately, there is no way to determine true NAS severity 
and thus the need to treat, and therefore, we cannot judge tools 
based on their true predictive accuracy. As a result, assessment 
tools will need to be judged based on existing knowledge about 
NAS severity; i.e., we need to use knowledge from up-to-date 
research and clinical experience to make an educated guess as 
to what the ideal model for severity should look like. Essentially, 
judgments will need to be based on face validity (22), and 
we want a tool based on utility (e.g., good perceived predic-
tive accuracy, or low disturbance based on Figures  3 and 4), 
practicality, and “clinical common sense” (22). Unfortunately, 
different people will have different judgments with respect to 
these considerations.
Specific judgments on a tool should be made with respect to 
three steps used to create an assessment tool based on a forma-
tive model (17). The first two steps consist of determining the 
potential variables to form the tool and ultimately deciding 
TABLe 2 | Considerations and obstacles in the evaluation and creation of 
Neonatal Abstinence Syndrome (NAS) assessment tools.
Basic considerations
Visualize what the ideal model would look like using knowledge from up-to-date 
research and clinical experience
 – Consider face validity; i.e., perceived clinical utility
 – Consider practicality; e.g., scoring time
 – Consider pharmacologic treatment cutoff values based on the ideal model
Differences in opinion
People can have varying opinions on a perceived ideal model. For instance, 
opinions can vary with respect to:
 – the utility of an item; i.e., is the item needed in the tool, and if so, how much 
weight should be assigned to the item?
 – the practicality of the item; e.g., does the amount of time it takes to score the 
item outweigh its added utility to the tool?
 – what treatment cutoff value(s) should be used, and how should they be used?
As a result of differences in opinion, perceived ideal assessment tools will also 
differ. This is one reason why new or modified assessment tools continue to be 
developed
issues in current practice
Advances in research and differences in opinion continue to result in different  
or modified tools being proposed and used. Examples include:
 – additions and reductions in the utilized items, as in the MOTHER NAS score 
(14, 15)
 – shortened tools
Empirical research on treatment cutoffs has used NAS as the outcome of 
interest, as opposed to the true need to treat, and can, therefore, only provide 
suggestive evidence with respect to the need for treatment
Judgments should not only consider inter-rater reliability, but also the utility of 
items when deciding whether or not to include the item in a tool
Future tools should be developed based on a formative modeling strategy and 
can be created by adding or reducing items from existing tools. Furthermore, 
other information can be used in conjunction with such tools
Assessment tools based on formative modeling can be developed to encompass 
a variety of exposure types
Tools tend to only be developed by a small group of people before being 
published and presumably used. Due to likely differences in opinion from other 
clinicians and researchers, implementation and ultimately standardization in 
practice is unlikely
To help standardize NAS assessment, experts should come together to decide 
on the best formative model(s) and ultimately assessment tool(s) to use
4
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which variables, or items, should actually be utilized. The third 
step is to determine how much weight should be assigned to each 
item. Furthermore, judgments must be made on the value of 
pharmacologic treatment cutoff scores, and how to use them. For 
instance, the decision to treat when using the FNAS is often based 
on whether or not three scores, or their average, of 8 in a row are 
observed (9–11), thus also implying two 12s in a row. A summary 
of basic considerations, as well as differences in opinion that are 
seen in practice, is given in Table  2. Table  2 also summarizes 
issues in current practice as discussed in the remainder of this 
manuscript.
eXAMPLeS
Although many people may not have realized the underlying 
theoretical framework, NAS assessment tools have been created 
via formative modeling approaches out of necessity. For instance, 
Finnegan et  al. (9, 10) used the three steps as just discussed. 
In brief, common symptoms were chosen based on the literature 
and experience, and weights assigned to each item were chosen 
based on pathologic significance. Furthermore, the treatment 
cutoff was chosen based on experience.
The fact that multiple modified versions of the FNAS exist, 
and that not even treatment cutoff scores are used consistently 
across institutions (5, 6), demonstrates the fact that people have 
formatively judged the FNAS and have determined it could use 
change. Multiple reasons for this exist. As time goes on, our 
knowledge with respect to NAS improves, and therefore, the way 
true NAS severity is perceived may change, thus alternating the 
way we want to model the construct of NAS severity. For instance, 
the MNS was created by Jansson et al. (14) to improve upon the 
FNAS. Both irritability and failure to thrive, based on weight loss, 
were added whereas some items were removed or combined, for 
instance, due to overlap. Furthermore, the FNAS is lengthy and 
clinicians may desire a shorter tool (28) that is more practical and 
potentially more reliably scored, and therefore, shortened scores 
have been proposed (29). Even a short functional assessment 
approach has been developed which is based on feeding, sleep-
ing, and ability to console when crying (30). We note that, unlike 
with a reflective model, heterogeneity of items in the assessment 
tool is clinically ideal as the use of correlated items unnecessarily 
adds time and complexity to scoring in practice.
An empirical approach that has been taken to formatively 
judge a NAS assessment tool, including its treatment cutoff 
value(s), is the use of data with the outcome of interest of whether 
or not the subject has NAS. Although this outcome is not ideal 
and will not provide definitive results because interest is actually 
in the unknown true need to treat, results can still be suggestive. 
For instance, Zimmerman-Baer et  al. (31) studied 102 healthy 
neonates and found that the 95th percentile of their scores, from 
a version of the FNAS comprised of 28 items, never exceeded 
8. Although this suggests that infants not in withdrawal will 
tend to have lower FNAS scores, and scores of 8 or above are 
mostly in infants who are withdrawing, this does not provide 
strong information with respect to the true need to treat infants 
in withdrawal. Specifically, interest is with respect to when NAS 
infants need to be treated, not if they actually have NAS. However, 
these particular results may be suggestive that, although a single 
score of 8 to deem treatment is needed is insufficient, an average 
of three 8s or two 12s in a row may suffice as adequate treatment 
cutoffs for this particular 28 item tool.
Although not a direct factor with respect to judging the 
formative nature of a tool, we feel it is important to note that the 
inter-rater reliability (IRR) of NAS assessment tools has received 
a notable amount of attention, as many items incorporated in 
NAS tools are based on subjective judgments. Although scorers 
should be trained, they may not always have complete agreement 
on the magnitude or occurrence of a clinical sign involved in a 
particular tool (23, 24). For instance, IRR coefficients have been 
shown, for example, to range from 0.70 (33) to 0.96 (9, 10) with 
the FNAS, 0.89 to 0.98 with the Neonatal Withdrawal Inventory 
(32), and greater than 0.94 with the MNS (5, 15). Furthermore, 
Gomez-Pomar et al. (33) showed that the degree of variance in 
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FNAS scores attributable to unreliable scoring is small (≤9.8% 
in the studied institutions). Although when viewed from a 
psychometric viewpoint, an interobserver reliability of 90% is 
desired (21, 34), there may still be enough utility in keeping any 
items in the tool that cause lack in IRR as opposed to removing 
them. Therefore, judgments should not only consider IRR, but 
also the utility of items. For instance, although it may be difficult 
to clearly distinguish the cutoffs between mild, moderate, and 
severe tremors, incorporation of this item with the chance of 
misclassification can still be more useful than not using this item 
simply because of this potential difficulty.
FUTURe TOOL DeveLOPMeNT
As more is learned about NAS, assessment tools may need to 
evolve. Based on a formative modeling approach, new items 
and their perceived impacts, via appropriate weights, can be 
added to tools, and numerical treatment cutoff values modified 
accordingly. Alternatively, items deemed to have little utility 
or practicality in the presence of other items can be removed. 
We do note that newer information, such as knowledge on genet-
ics and the mother’s prenatal treatment (5), may be difficult to 
incorporate into a standard assessment tool. However, research 
could be conducted on how to best utilize such information in 
conjunction with the tool. For instance, Grossman et  al. (30) 
recently demonstrated that a simple functional assessment can 
work well when combined with other novel strategies for NAS 
management.
Formative models can also conform to variations that exist in 
practice and that should be considered for future tool develop-
ment. Presenting NAS symptoms may depend on the type of 
opioid causing withdrawal, among other possible factors (6, 13, 
21, 35). Furthermore, many infants’ withdrawal can be a result 
from exposures to multiple types of drugs, which would not 
correspond to a single opioid-based tool. This issue is amplified 
when there is also exposure to non-opioids (21, 36). Extending 
upon the issue of heterogeneous exposures, variations in the 
distributions of exposure types may also exist across different 
institutions due to the different populations they care for (33). All 
of these variations will contribute to a lack in correlation among 
items in as assessment tool, and thus the tool will be deemed 
inappropriate if based on a reflective modeling viewpoint. 
However, when based on a formative model, a tool is allowed to 
encompass the spectrum of opioids. Specifically, this modeling 
approach allows us to simultaneously assess symptoms from 
different types of exposures, thus building up a case for the need 
to treat. This is important because it is clinically irrelevant to 
restrict the applicability of a tool to a single exposure type when 
in real life we are faced with multidrug-exposed withdrawing 
infants (37). We do note, however, that this issue adds a notable 
degree of complexity in terms of judging the utility of any such 
tool, and multiple tools may be required; e.g., a unique tool for 
a single or specific mixture of exposures, or even a unique tool 
for institutions observing similar distributions in exposures. 
Unfortunately, no existing or future tools will be ideal, but we 
hope to obtain the best guidance as practically possible from 
these tools (28).
Major contributing factors to the existence of a variety of 
NAS assessment tools include the fact that researchers have been 
independently judging and creating these tools and differences 
in opinion exist. As a result, it is very difficult for any new tool 
to be widely assessed and ultimately implemented in practice, as 
other clinicians and researchers may not agree with the proposed 
tool in terms of its utility and practicality. Therefore, we urge that 
a large group of experts in the area of NAS assessment should 
come together and pool their knowledge and clinical experi-
ence to assess the utility and practicality of existing assessment 
tools and to determine if one or more new or modified tools 
are needed. If needed, such “best” tools should be formulated 
with consideration of both perceived utility and practicality 
based on a formative modeling strategy. We suspect there will 
never be complete agreement and, therefore, compromises and 
ultimately a consensus in terms of the included items and the 
assigned weights to each item is likely needed (17). Furthermore, 
randomized clinical trials may be warranted to confirm the 
superiority of any such tools to existing tools on outcomes of 
importance such as length of stay and duration of opioid treat-
ment (13, 38).
CONCLUSiON
There is push in the NAS literature on the need for a new 
assessment tool that is psychometrically valid (21). However, 
this inherent proposed use of a reflective model does not 
correspond to the real-world diversity of NAS manifesta-
tions observed in practice and the fact that numerical scores 
from an assessment tool do not completely dictate the deci-
sion to start pharmacological treatment. Therefore, in this 
manuscript, we argue that judgments on, and therefore future 
development of, NAS assessment tools should be based on 
a formative modeling approach. Such an approach can take 
into account the complexity of the presenting symptoms of 
NAS, their severity, and potentially the fact that heterogeneity 
of symptoms and their severity exists across different types 
and mixtures of opioid exposures. Finally, current assessment 
tools must be judged using current knowledge and experience, 
and judgment can vary in opinion. Therefore, one or more 
assessment tools based on a formative model and created 
based on the input of a large group of experts may be needed 
in order to lead to increased agreement on the assessment of 
NAS in practice.
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